Oxidative stress markers during a course of hyperthyroidism by Lampka, Magdalena et al.
218
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 57; Numer/Number 3/2006
ISSN 0423–104X
Streszczenie
Wstęp: Wcześniejsze badania wskazują na występowanie
stresu oksydacyjnego w stanach nadczynności tarczycy. Ce-
lem niniejszej pracy była ocena wpływu nadczynności tar-
czycy na procesy peroksydacji lipidów, oksydację lipopro-
tein osocza oraz stan antyoksydacyjny organizmu. Ocenia-
no przydatność oznaczanych parametrów biochemicznych
jako wskaźników stresu oksydacyjnego w hipertyreozie.
Materiał i metody: Badaniami objęto 25 pacjentów z jawną
nadczynnością tarczycy w przebiegu choroby Gravesa-Ba-
sedowa lub wola guzkowego nadczynnego oraz 20 zdrowych
ochotników stanowiących grupę kontrolną. Nasilenie pro-
cesów peroksydacji lipidów oceniano poprzez pomiar stę-
żenia nadtlenków lipidów oraz pomiar stężenia dialdehy-
du malonowego oznaczanego łącznie z 4-hydroksynone-
nalem w surowicy (MDA + 4-HNE). Wskaźnikiem oksyda-
cji lipoprotein było stężenie przeciwciał przeciwko
oksydowanym LDL (anti-oxLDL, autoantibodies against oxi-
dised LDL). Zmiany w systemie obrony antyoksydacyjnej
organizmu oceniano poprzez pomiar całkowitego stanu
antyoksydacyjnego surowicy (TAS, total antioxidant status
in serum) oraz aktywność dysmutazy ponadtlenkowej ery-
trocytów (SOD, superoxide dismutase activity).
Wyniki: W badanej grupie pacjentów z nadczynnością tar-
czycy obserwowano zwiększone stężenie produktów pe-
roksydacji lipidów w surowicy, zarówno nadtlenków, jak
i MDA + 4-HNE. Nie stwierdzono istotnych statystycznie
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różnic między grupą badaną a kontrolną w stężeniu prze-
ciwciał przeciwko oksydowanym LDL oraz w wartościach
wskaźników obrony antyoksydacyjnej organizmu (TAS,
SOD).
Wnioski: Wyniki badań wskazują na nasilenie przemian
oksydacyjnych wywołanych działaniem wysokich stężeń
hormonów tarczycy, któremu nie towarzyszy odpowiedź
systemu antyoksydacyjnego organizmu. Podwyższone stę-
żenie produktów peroksydacji lipidów w surowicy, zarów-
no nadtlenków, jak i dialdehydu malonowego oraz 4-hy-
droksynonenalu, może być użytecznym wskaźnikiem stre-
su oksydacyjnego w przebiegu nadczynności tarczycy.
(Endokrynol Pol 2006; 3 (57): 218–222)
Słowa kluczowe: nadczynność tarczycy, stres oksydacyjny,
peroksydacja lipidów, oksydacja LDL, autoprzeciwciała
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Abstract
Introduction: Previous studies have shown the presence
of oxidative stress in hyperthyroid patients. The aim of this
study was to evaluate the influence of hyperthyroidism on
lipid peroxidation, plasma lipoprotein oxidation and antio-
xidant status. We have estimated the clinical utility of the
biochemical parameters analysed as markers of oxidative
stress in hyperthyroidism.
Material and methods: Twenty five patients with overt hy-
perthyroidism because of Graves’ disease or toxic multino-
dular goitre and 20 healthy subjects were included in the
study. Lipid peroxidation was evaluated by measurement
of peroxides and malondialdehyde with 4-hydroxynone-
nal (MDA + 4-HNE) concentrations. Autoantibodies aga-
inst oxidised LDL (anti-oxLDL) were assayed as a marker
of lipoprotein oxidation. Changes in the antioxidant defen-
ce system were estimated by measurement of total antioxi-
dant status in serum (TAS) and erythrocyte superoxide di-
smutase activity (SOD).
Results: A significant increase in serum concentration of
peroxides and MDA + 4-HNE was observed in patients with
hyperthyroidism. However, no difference was found in anti-
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oxLDL concentration and antioxidant status parameters
(TAS, SOD) between the control group and the patient group.
Conclusions: Our results indicate an intensification of the
oxidative processes caused by an excess of thyroid hormo-
nes, which is not accompanied by a response from the an-
tioxidant system. Elevated concentrations of lipid peroxi-
dation products in serum, both peroxides and malondial-
dehyde with 4-hydroxynonenal, may be useful as markers
of oxidative stress during the course of hyperthyroidism.
(J Pol Endocrinol 2006; 3 (57): 218–222)
Key words: hyperthyroidism, oxidative stress, lipid
peroxidation, LDL oxidation, autoantibodies
Introduction
Oxidative stress accompanying hyperthyroidism is cau-
sed by increased synthesis of reactive oxygen species and
changes in the antioxidant defence system. An elevated
metabolic rate and acceleration of oxygen consumption
in hyperthyroidism leads to increased generation of re-
active oxygen species. The antioxidant defence system
includes both enzymatic and non-enzymatic compo-
nents. The antioxidant enzymes comprise superoxide
dismutase, glutathione peroxidase and catalase. Non-
enzymatic small molecules that act as antioxidants inclu-
de vitamins E and C, glutathione and coenzyme Q [1–4].
Both stimulation and inhibition of antioxidant enzyme
activity were observed in hyperthyroidism [1, 2, 4]. Chan-
ges in concentration of non-enzymatic components were
also noted in hyperthyroidism [3, 5].
An enhanced generation of reactive oxygen species con-
comitant with inactivation of the antioxidant systems leads
to intensified cellular lipid peroxidation [1]. Hyperthyroidism
is associated with an increase in lipid peroxidation product
concentration in the blood of patients. Lipid peroxidation may
be estimated by measurement of primary products (con-
jugated dienes, peroxides) as well as the final products of
this process (malondialdehyde, 4-hydroxynonenal) [1, 6].
 Intensification of lipid peroxidation in patients with
hyperthyroidism may be accompanied by an increase
in oxidative modification of plasma lipoproteins [7–9].
Reactive oxygen species generated in artery walls par-
ticipate in a low-density lipoprotein oxidation process.
These lipoproteins display immunogenic properties and
therefore autoantibodies against oxidised LDL produ-
ced by the immune system may be used as markers of
lipoprotein oxidation [10].
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The aim of our study was to evaluate the effect of
hyperthyroidism on the lipid peroxidation process and
plasma lipoprotein oxidation and to estimate antioxidant
status. We evaluated the utility of some biochemical pa-
rameters as oxidative stress markers in hyperthyroidism.
Material and methods
Twenty five patients (21 women and 4 men) with overt
hyperthyroidism were investigated. Eight patients were
diagnosed with Graves’ disease and 17 with toxic mul-
tinodular goitre. Diagnosis of hyperthyroidism was ba-
sed on clinical examination and was confirmed by me-
asurement of thyroid stimulating hormone (TSH) and
thyroid hormone levels. The age of the patients ranged
from 27 to 76. The control group included 20 healthy
subjects (18 women and 2 men) of 26 — 68 years with
normal TSH concentration.
Heparinised blood was used to determine SOD acti-
vity in erythrocytes. The remaining parameters were
assayed in serum. Serum and erythrocyte lysates were
stored at –70°C until assayed. Malondialdehyde concen-
tration was assayed in combination with 4-hydroxyno-
nenal using a commercially available kit, Bioxytech
LPO-586 (Oxis, USA). Peroxide concentration was me-
asured with OxyStat, and autoantibodies against oxidi-
sed LDL — oLAB by ELISA (Biomedica, Austria). Total
antioxidant status and superoxide dismutase activity
were assayed by TAS and Ransod kits (Randox Labora-
tories, UK). Total cholesterol and triglyceride concen-
trations were measured by the enzymatic method and
HDL cholesterol concentration by a precipitation me-
thod. LDL cholesterol concentration was calculated by
Friedewald’s formula. TSH, FT4 and FT3 were measu-
red by electrochemiluminescence immunoassay (Elec-
sys, Roche) in the Department of Laboratory Medicine.
FT3 concentration was determined only in the group of
patients with hyperthyroidism. Results were expressed
as median and range. The Mann-Whitney U test was
used to determine whether differences between the
control group and patient group were significant, with
p < 0.05 taken as statistically significant.
Results
The values of the laboratory parameters evaluated in hy-
perthyroid patients and in the control group are presen-
ted in Tables I and II. For each parameter median value
and the range from minimum to maximum are provided.
Parameters describing thyroid function and serum
lipid profile are reported in Table I. Serum concentra-
tions of TSH and FT4 in the control group were within
the range of reference values. Statistical analysis revealed
that patients with hyperthyroidism were characterised
by significantly decreased total cholesterol (p < 0.01), LDL
cholesterol (p < 0.05) and HDL cholesterol (p < 0.01)
Table I
Thyroid function parameters and serum lipid profile in hyperthyroid patients (n = 25)
and control subjects (n = 20)
Tabela I
Parametry czynności tarczycy i profil lipidowy surowicy u chorych na nadczynność
tarczycy (n = 25) i u osób z grupy kontrolnej (n = 20)
Laboratory parameters Hyperthyroid patients Control group
(reference values) Median Median
(min–max) (min–max)
TSH [mIU/l] 0.0012*** 1.2790
(0.3500–4.9400) (0.0001–0.0840) (0.4064–2.5440)
FT4 [ng/dl] 1.94*** 0.940
(0.70–1.48) (0.74–15.00) (0.80–1.16)
FT3 [pg/ml] 5.50
(1.71–3.71) (3.76–30.00)
Total cholesterol [mg/dl] 171** 207
(< 200) (110–235) (135–289)
LDL cholesterol [mg/dl] 112* 130
(< 130) (50–174) (55–226)
HDL cholesterol [mg/dl] 49** 62
(> 35) (25–77) (45–98)
Triglycerides [mg/dl] 93* 74
(< 150) (45–205) (32–155)
Statistical significance versus the control group; * p < 0.05, ** p < 0.01, *** p < 0.001
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values but elevated triglycerides (p < 0.05) compared
to the control group.
Lipid peroxidation indices, lipoprotein oxidation
marker and values of antioxidant system parameters are
shown in Table II. We found a significant elevation of
lipid peroxidation products, both peroxides (p < 0.001)
and MDA + 4-HNE (p < 0.01), in patients with hyper-
thyroidism. No significant difference was observed be-
tween patients and the control group in the concentra-
tion of autoantibodies against oxidised LDL (anti-
oxLDL). TAS and erythrocyte SOD activity did not chan-
ge in patients with hyperthyroidism.
Discussion
The present study demonstrates an intensification of
the lipid peroxidation process in hyperthyroidism. Ele-
vated peroxide as well as malondialdehyde and 4-hy-
droxynonenal concentrations were found in the serum
of patients with hyperthyroidism. Our results are in
agreement with the data of others [1–5]. According to
Komosinska-Vassev et al. [1], Ademoglu et al. [5] and
Seven et al. [11], increased lipid peroxidation is associa-
ted with an excess of thyroid hormones, while inhibi-
tion of peroxidation takes place in the euthyroid state
after antithyroid treatment.
Elevated lipid peroxidation may be accompanied by
intensified plasma lipoprotein oxidation. Elevated LDL
oxidation in patients with hyperthyroidism was noted
by Costantini et al. [7] and Sundaram et al. [8]. Both
authors used measurement of lipid peroxidation pro-
duct concentration in isolated LDL. Dirican and Tas [9]
have also shown increased LDL susceptibility to oxida-
tion in experimental hyperthyroidism.
In our study autoantibodies against oxidised LDL
were assayed as a lipoprotein oxidation marker, altho-
ugh their concentration did not differ significantly be-
tween the examined group and the control group. No
significant changes in concentration of anti-ox LDL in
hyperthyroidism were reported by Resch et al. [12]
either. Autoantibodies against oxidised LDL concentra-
tion have been used as a marker of LDL oxidative mo-
dification by numerous authors, mainly in patients with
coronary artery disease [13, 14]. However, other studies
have shown that anti-oxLDL concentration is in an in-
verse relationship with plasma oxLDL concentration in
healthy subjects [15] and that synthesis of these auto-
antibodies depends on age [16]. This parameter may
also be a marker of total antibody production in the orga-
nism, especially in autoimmune disease [16]. Therefore
serum anti-oxLDL concentration does not seem to be
a good marker of oxidative stress in hyperthyroidism.
We encountered a number of problems in evaluating
LDL oxidation in hyperthyroidism because many dif-
ferent factors have an influence on this process. The
increased generation of reactive oxygen species in hy-
perthyroidism may contribute to intensified LDL oxi-
dative modification but, at the same time, a decreased
concentration of these lipoproteins in serum, caused by
intensified catabolism, may reduce their oxidation ef-
fect. A decrease in LDL lipoprotein level in hyperthy-
roidism is manifested by low cholesterol concentration
in serum. Significantly decreased total cholesterol and
LDL cholesterol concentrations were noted in the
Table II
Parameters of lipid peroxidation, LDL oxidation and antioxidant system in hyperthyroid
patients (n = 25) and control subjects (n = 20)
Table II
Parametry peroksydacji lipidów, oksydacji LDL oraz układu antyoksydacyjnego u chorych
na nadczynność tarczycy (n = 25) oraz u osób z grupy kontrolnej (n = 20)
Laboratory parameters Hyperthyroid patients Control group
Median Median
(min–max) (min–max)
Peroxides 340 *** 47
[mmol/l] (34–1037) (30–520)
MDA + 4-HNE 1.52** 0.97
[mmol/l] (0.40–2.80) (0.40–2.02)
anti-oxLDL 332 450
[mU/ml] (161–2457) (138–2099)
TAS 1.53 1.49
[mmol/l] (1.17–1.83) (1.33–1.88)
SOD 1197 1086
[U/g Hb] (800–2158) (738–1935)
Statistical significance versus the control group; **p < 0.01; ***p < 0.001
222
Oxidative stress markers during a course of hyperthyroidism Magdalena Lampka i wsp.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
patient group. The factor that might directly inhibit oxi-
dative modification of low density lipoprotein is thyro-
xine. Examination in vitro revealed that thyronine ana-
logue L-T4 in the physiological concentration inhibited
LDL oxidation [17].
 Lipid peroxidation intensification may also be cau-
sed by a reduced antioxidative defence of the organism.
In our study changes in total antioxidant status were
not noted in patients with hyperthyroidism in compari-
son with the control group. Komosinska-Vassev et al. [1]
noted a decrease in TAS values in the serum of patients
with Graves’ disease and its elevation after antithyroid
treatment. Resch et al. [12] noted a decrease in non-en-
zymatic antioxidant concentration and enzymatic acti-
vity intensification in hyperthyroidism. In our exami-
nation no significant changes in SOD activity were no-
ted in patients with hyperthyroidism. The superoxide
dismutase activity is characterised by non-specific chan-
ges in the course of hyperthyroidism. Both an eleva-
tion [1, 11, 18] and a decrease [19] in erythrocyte SOD
activity were reported in patients with hyperthyroidism.
These differences in antioxidant enzyme activity
may be caused by various mechanisms. The reactive
oxygen species contribute to an intensified synthesis of
antioxidant enzymes in tissues and hence their eleva-
ted activity may be a manifestation of adaptation me-
chanisms in response to oxidative stress. A decreased
activity of antioxidant enzymes or a decreased non-en-
zymatic antioxidant concentration may be caused by
their intensified utilisation in protection against oxida-
tive damage to tissues [1, 18]. There are a number of
factors that may influence antioxidant system activity.
In experimental examination on animals, antioxidant
enzyme activity was affected by the age of animals with
induced hyperthyroidism [20].
In our examination no adaptive changes in the an-
tioxidant defence system of the organism were noted
in patients with hyperthyroidism. Therefore determi-
nation of antioxidant enzyme activity and non-enzy-
matic antioxidant concentration seems to be less useful
in the evaluation of oxidative stress in hyperthyroidism.
 Conclusions
Our results indicate intensification of the oxidative pro-
cesses caused by thyroid hormone excess, which are not
accompanied by an adaptive response of the antioxi-
dant system. An augmented concentration of lipid pe-
roxidation products in serum, both peroxides and ma-
londialdehyde with 4-hydroxynonenal, may constitu-
te a useful marker of oxidative stress in the course of
hyperthyroidism.
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